Clinical trial
Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
NCT00105287 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00105287 |
|---|---|
| Title | Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients |
| Official title | Multi-center Study Evaluating OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pain, Cancer |
| Intervention type | Drug |
| Interventions | OraVescent fentanyl (OVF) |
| Enrollment | 100 |
| Start date | Jan 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Mar 14, 2005 |
| Last update posted | May 9, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: